CGEM
Cullinan Therapeutics, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$15.03Close
$905.5MMarket cap
$7.19 – $22.9552-week range
Nov 5, 2026Next report
Highlights
Strengths
- Leading the market RS 80 · stronger than 80% of stocks over 12 months
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Far from its high 35% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
35%
1wk
up 4.6%
price change
1mo
down 2.1%
price change
12-month return
up 99%
market up 11% ·
its own up 85%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.2×
price / book
Earnings yield
down 29.6%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 44%
return on equity
Free cash margin
—
-$175.8M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.4%
$0.96 a day · 2×ATR $13.11
RS
80 / 99
vs the universe
Trend
5 / 8
under the 150/200-day, under the 50-day, over 25% off the high
Relative volume
0.4×
vs 50-day average
Up/down volume
0.79
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 5 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 3.0% over the year, from 59m to 60m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Last shock
Sep 23, 2026-22% in one session3.3× volumeon an SEC filing-11% since
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $18.9M | $0 | — | — | — |
| Operating income | -$60.3M | -$68.0M | $144.6M | -$191.1M | -$196.9M | -$241.6M |
| Net income | -$51.8M | -$65.6M | $111.2M | -$155.1M | -$167.6M | -$219.9M |
| Net margin | — | -346% | — | — | — | — |
| Earnings per share | — | -$1.52 | $2.38 | -$3.73 | — | — |
| Free cash flow | -$29.8M | -$43.4M | -$127.8M | -$134.5M | -$145.3M | -$175.8M |
| Free cash margin | — | -229% | — | — | — | — |
| Cash | $168.2M | $59.8M | $156.2M | $98.4M | $83.0M | $88.3M |
| Shareholders' equity | $199.0M | $425.0M | $535.0M | $453.7M | $590.3M | $408.7M |
| Shares outstanding | 29.83m | 44.29m | 45.80m | 42.90m | 58.51m | 60.24m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 10, 2026 | Annual ↗ | Dec 31, 2025 | 69d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 15, 2024 | Quarterly ↗ | Mar 31, 2024 | 45d |
| Mar 14, 2024 | Annual ↗ | Dec 31, 2023 | 74d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 2, 2026 | Regulation FD · Other events ↗ |
| Sep 24, 2026 | Regulation FD · Other events ↗ |
| Sep 14, 2026 | Regulation FD · Other events ↗ |
| Aug 13, 2026 | Regulation FD · Other events ↗ |
| Aug 6, 2026 | Results ↗ |
| Jun 16, 2026 | Shareholder vote ↗ |
| Jun 10, 2026 | Regulation FD · Other events ↗ |
| Jun 8, 2026 | Regulation FD · Other events ↗ |
| May 18, 2026 | Regulation FD · Other events ↗ |
| May 7, 2026 | Results ↗ |
| Mar 10, 2026 | Results ↗ |
| Jan 8, 2026 | Results · Regulation FD · Other events ↗ |